- Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced results from the ARC-HD trial, an approximately 3-year open-label study evaluating the safety and tolerability of long-term treatment with Austedo (deutetrabenazine) tablets for chorea associated with Huntington’s Disease (HD).
- ARC-HD results showed that treatment with Austedo had a safety and tolerability profile comparable with the First-HD 12-week study.
- In ARC-HD, medication compliance rates were greater than 90% over the ~3 year open-label extension period.
- Austedo improved and maintained chorea control in the Rollover and Switch cohorts.
- In patients who rolled over from the pivotal study, from baseline to Week 8, there was a 4.5-point reduction in mean chorea scores. 7.1-point reduction in the mean total motor score (TMS).
- In patients who switched overnight from tetrabenazine, from baseline to Week 8 there was a 2.1-point reduction in mean chorea scores and a 2.4-point reduction in mean TMS.
- Price Action: TEVA shares are up 2.14% at $8.36 on the last check Tuesday.
Hoth Therapeutics’ Investigational Cancer Drug Shows Encouraging Preclinical Activity In Stomach Cancers
Hoth Therapeutics Inc (NASDAQ: HOTH) announced that HT-KIT, a new molecular entity for advance systemic mastocytosis, achieved
